0001839882-23-013974.txt : 20230530 0001839882-23-013974.hdr.sgml : 20230530 20230530181444 ACCESSION NUMBER: 0001839882-23-013974 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230525 FILED AS OF DATE: 20230530 DATE AS OF CHANGE: 20230530 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versi Jannine CENTRAL INDEX KEY: 0001977745 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 23978247 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: STE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 4 1 jversi-form4_052523.xml OWNERSHIP DOCUMENT X0407 4 2023-05-25 0 0000887247 Adamis Pharmaceuticals Corp ADMP 0001977745 Versi Jannine C/O ADAMIS PHARMACEUTICALS CORPORATION 11682 EL CAMINO REAL, SUITE 300 SAN DIEGO CA 92130 1 0 0 0 0 Common Stock 2023-05-25 4 A 0 177194 A 177194 I By Versi Group, LLC Employee Stock Option (Right to Buy) 2.90 2023-05-25 4 A 0 5144 A 2023-05-25 2028-02-19 Common Stock 5144 5144 D Employee Stock Option (Right to Buy) 2.90 2023-05-25 4 A 0 5144 A 2023-05-25 2029-02-19 Common Stock 5144 5144 D Employee Stock Option (Right to Buy) 2.90 2023-05-25 4 A 0 5144 A 2023-05-25 2030-02-19 Common Stock 5144 5144 D Employee Stock Option (Right to Buy) 2.90 2023-05-25 4 A 0 5144 A 2023-05-25 2031-02-19 Common Stock 5144 5144 D Employee Stock Option (Right to Buy) 2.90 2023-05-25 4 A 0 5144 A 2023-05-25 2032-02-19 Common Stock 5144 5144 D Series E Convertible Preferred Stock 2023-05-25 4 A 0 1941.2 A 2023-05-25 Common Stock 1941200 1941.2 I By Versi Group, LLC On May 22, 2023, Adamis Pharmaceuticals Corporation ("Adamis") effected a 1 for 70 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. The reported shares are owned directly by Versi Group, LLC, of which the reporting person is the trustee of. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interests therein. Received in exchange for shares of common stock of DMK Pharmaceuticals Corporation, a privately held corporation ("DMK"), in connection with the merger of DMK into a subsidiary of Adamis (the "Merger"). On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share. Received in the Merger by virtue of the assumption of a stock option to acquire shares of DMK common stock in connection with the Merger, with proportionate adjustments to the number of shares subject to the option and the per share exercise price. Received in the Merger in exchange for shares of common stock of DMK. Each whole share of Series E Preferred Convertible Stock is convertible into 1,000 shares of Adamis common stock at the election of the Reporting Person provided that no portion of the Series E Convertible Preferred Stock may be converted if the Reporting Person or her affiliates own in excess of 9.99% of the number of shares of Adamis common stock outstanding immediately after giving effect of such conversion. On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share. /s/ David C. Benedicto, as Attorney-in-Fact 2023-05-30